SCHEMBL3706797

SCHEMBL3706797

COc1ccc(CC(=O)Nc2nn3cc(C)cnc3c2-c2ccc(Cl)cc2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.51
KCNQ2 O43526 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.48
KDR P35968 1/20 0.48
EPHX2 P34913 1/20 0.47
LMNA P02545 4/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
GAA P10253 1/20 0.45
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
ALPL P05186 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3695326 0.85 KCNQ3 (0.57) KCNQ3KCNQ2SMN1; SMN2LMNAALDH1A1
SCHEMBL3696279 0.85 KCNQ3 (0.52) KCNQ3KCNQ2SMN1; SMN2LMNAALDH1A1
SCHEMBL3704649 0.80 KCNQ3 (0.50) KCNQ3KCNQ2SMN1; SMN2LMNAKDM4E
SCHEMBL3708663 0.79 KCNQ2 (0.52) KCNQ3KCNQ2ALDH1A1KMT2AGAA
SCHEMBL3698068 0.78 KCNQ3 (0.49) KCNQ3KCNQ2SMN1; SMN2LMNAMAPT
SCHEMBL3703621 0.76 KCNQ3 (0.58) KCNQ3KCNQ2SMN1; SMN2LMNAKDM4E
SCHEMBL3699241 0.76 KCNQ3 (0.51) KCNQ3KCNQ2ALDH1A1TP53
SCHEMBL3706860 0.75 MAPK14 (0.56) KCNQ3KCNQ2SMN1; SMN2LMNAALDH1A1
SCHEMBL3698911 0.73 KCNQ3 (0.56) KCNQ3KCNQ2SMN1; SMN2LMNAKDM4E
SCHEMBL3698144 0.72 KCNQ3 (0.53) KCNQ3KCNQ2TP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US claimed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO claimed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US disclosed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122888-A1 Potassium Channel Modulators KCNQ1, KCNQ2, KCNJ2 KCNQ3 4/4885KCNQ2 2/4885SMN1; SMN2 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.